Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI

Recruiting N/A Interventional Study
Coronary Artery Disease Coronary Occlusion Percutaneous Coronary Intervention
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
74 (estimated)
Sponsor
National Institute of Cardiology, Warsaw, Poland · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The ADRENALINE trial has been designed as a multi-center, prospective randomized study to compare the procedural and periprocedural outcomes of coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using antegrade dissection and re-entry (ADR) versus retrograde strategy. Beyond the patient-oriented outcomes, the influence of the studied CTO PCI strategies on the stress le…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * clinical indication for CTO PCI as determined by the local heart team (presence of angina or equivalent symptoms and/or documented ischemia or viability) * at least difficult native CTO lesion with J-CTO difficulty score ≥2 points on invasive angiography * angiographic suitabi…
Contacts

Katarzyna Istynowicz

0048223434268

kistynowicz@ikard.pl

CONTACT

Wioletta Antos

0048223434268

wantos@ikard.pl

CONTACT